Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by JDavenporton May 03, 2022 11:56am
163 Views
Post# 34651311

RE:value

RE:value
Some of you are correct if you think my answer to Rosie1965's "share price" question was a little flippant. Rosie1965 is a new Stockhouse member who, at the point of this writing, has made two posts. After welcoming them aboard, I would like to point out that their first post was a question about foreign interest in Bioasis and xB3. It didn't take much to dispose of that attempt to ridicule Bioasis and its shareholders, if it was intended as such, as I suspect it was.
 
In my opinion, Rosie1965's second post was a trap, an attempt to get some sort of outrageous answer from me that they could ridicule. But, in fact, I've been saying for a long time that the value of Bioasis on any given day is what the market says it is, no more no less. I get chrispi's view that Bioasis's value could be assessed by the potential deals and other successes that shareholders should be expecting. On that basis, Bioasis should be at a higher price but after all this time with few accomplishments, and with the spectre of an undervalued "accretive" merger or acquisition being predicted by Bioasis's main promoter, gee, it's hard to look to $5.00 or $10.00 because the company may not exist at a point when those numbers would make sense.
 
If Bioasis remained under the control of current shareholders, at least until the company accomplished something like a phase 1b success with xB3-001, who could doubt that the share price would shoot up. We could even see value given in the market for not only xB3-001 but for the entire in-house and partnered pipeline because, although the treatment of brain tumours is a big story, so is the safe and efficacious delivery of all drugs into the CNS that would be beneficial.

And Bioasis could have a big lock on a lot of that business. When it's realized that Bioasis can construct and control already-proven payloads as xB3-drugs, a benefit that essentially eliminates expensive R&D, that could further enhance the value of Bioasis shares. It's broadly recognized, by virtue of the market's assessment of Denali, that the transport of drugs into the CNS is a big deal.
 
About Rosie, their questions just give us another chance to discuss these things, regardless of their intentions on this forum.
 
jd
<< Previous
Bullboard Posts
Next >>